Exploratory Clinical Study of Targeted Activated DC and CAR-T Therapy in Advanced Solid Cancers

This is an open-label, single-arm clinical study designed to evaluate the safety and preliminary efficacy of Targeted Activated DC combined with CAR-T therapy in patients with Advanced Solid Cancers.This combination therapy activates dendritic cells (DCs) to precisely target the tumor site, reshaping the tumor immune microenvironment, breaking down the immunosuppressive barrier, and allowing CAR-T cells to penetrate deeper into the tumor more efficiently, precisely and persistently killing cancer cells.

NCT Number	NCT07475182
Lead Sponsor	Hainan Cancer Hospital Collaborators: Frontiergate Biopharm（Hainan） Co., LTD
Conditions	Advanced Solid Cancers
Enrollment	10 participants
Start Date	2025-12-06
Primary Completion	2027-12-06 (estimated)
Study Completion	2028-06-06 (estimated)
Updated on ClinicalTrials.gov	2026-03-16